🇺🇸 FDA
Pipeline program

SPN-812

812P412

Approved small_molecule completed

Quick answer

SPN-812 for Attention-Deficit/Hyperactivity Disorder (ADHD) is a Approved program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
SUPERNUS PHARMACEUTICALS, INC.
Indication
Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials